The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)

Launched by FONDAZIONE RICERCA TRASLAZIONALE · Jan 22, 2019

Keywords

ClinConnect Summary

We will retrospectively analyze patients with advanced NSCLC who have received at least one cycle of nivolumab (3mg/kg intravenously every 2 weeks) within the early access program (EAP) or after the drug approval. All patients have been treated with immunotherapy, in second or further line, in two Italian Institution (the S. Maria delle Croci Hospital in Ravenna and the S. Maria della Misericordia Hospital in Perugia) between February 2015 and May 2017.

Patient data and laboratory values will be recorded in an electronic anonymized database and personally collected by one of the investigat...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with histologic diagnosis of advanced NSCLC who received Nivolumab as second or further line of therapy
• • Paraffin-embedded tissue sample available for PD-L1 analysis
• • disponibilità di emocromo entro 4 settimane dall'inizio del trattamento con Nivolumab
• • To calculate NLR, the absolute neutrophil count was divided by the lymphocytes value measured in peripheral blood within 4 weeks prior to the first infusion of nivolumab.
• • No main Exclusion Criteria